| Title |
Selective phosphodiesterase inhibitors: a promising target for cognition enhancement
|
|---|---|
| Published in |
Psychopharmacology, August 2008
|
| DOI | 10.1007/s00213-008-1273-x |
| Pubmed ID | |
| Authors |
Olga A. H. Reneerkens, Kris Rutten, Harry W. M. Steinbusch, Arjan Blokland, Jos Prickaerts |
| Abstract |
One of the major complaints most people face during aging is an impairment in cognitive functioning. This has a negative impact on the quality of daily life and is even more prominent in patients suffering from neurodegenerative and psychiatric disorders including Alzheimer's disease, schizophrenia, and depression. So far, the majority of cognition enhancers are generally targeting one particular neurotransmitter system. However, recently phosphodiesterases (PDEs) have gained increased attention as a potential new target for cognition enhancement. Inhibition of PDEs increases the intracellular availability of the second messengers cGMP and/or cAMP. |
Mendeley readers
The data shown below were compiled from readership statistics for 241 Mendeley readers of this research output. Click here to see the associated Mendeley record.
Geographical breakdown
| Country | Count | As % |
|---|---|---|
| United States | 5 | 2% |
| Germany | 3 | 1% |
| Sweden | 2 | <1% |
| India | 2 | <1% |
| Brazil | 1 | <1% |
| Netherlands | 1 | <1% |
| Colombia | 1 | <1% |
| Kazakhstan | 1 | <1% |
| Unknown | 225 | 93% |
Demographic breakdown
| Readers by professional status | Count | As % |
|---|---|---|
| Researcher | 56 | 23% |
| Student > Ph. D. Student | 39 | 16% |
| Student > Master | 28 | 12% |
| Student > Bachelor | 25 | 10% |
| Professor | 11 | 5% |
| Other | 52 | 22% |
| Unknown | 30 | 12% |
| Readers by discipline | Count | As % |
|---|---|---|
| Agricultural and Biological Sciences | 55 | 23% |
| Medicine and Dentistry | 38 | 16% |
| Neuroscience | 31 | 13% |
| Pharmacology, Toxicology and Pharmaceutical Science | 18 | 7% |
| Biochemistry, Genetics and Molecular Biology | 16 | 7% |
| Other | 42 | 17% |
| Unknown | 41 | 17% |
Attention Score in Context
This research output has an Altmetric Attention Score of 10. This is our high-level measure of the quality and quantity of online attention that it has received. This Attention Score, as well as the ranking and number of research outputs shown below, was calculated when the research output was last mentioned on 23 July 2019.
All research outputs
#3,193,858
of 22,789,566 outputs
Outputs from Psychopharmacology
#812
of 5,346 outputs
Outputs of similar age
#8,201
of 68,871 outputs
Outputs of similar age from Psychopharmacology
#8
of 39 outputs
Altmetric has tracked 22,789,566 research outputs across all sources so far. Compared to these this one has done well and is in the 85th percentile: it's in the top 25% of all research outputs ever tracked by Altmetric.
So far Altmetric has tracked 5,346 research outputs from this source. They typically receive a lot more attention than average, with a mean Attention Score of 10.6. This one has done well, scoring higher than 84% of its peers.
Older research outputs will score higher simply because they've had more time to accumulate mentions. To account for age we can compare this Altmetric Attention Score to the 68,871 tracked outputs that were published within six weeks on either side of this one in any source. This one has done well, scoring higher than 88% of its contemporaries.
We're also able to compare this research output to 39 others from the same source and published within six weeks on either side of this one. This one has done well, scoring higher than 79% of its contemporaries.